Onset of effect of budesonide and formoterol administered via one pressurized metered-dose inhaler in patients with asthma previously treated with inhaled corticosteroids

Annals of Allergy, Asthma and Immunology

Volumn 101, Issue 3, 2008, Pages 295-303

  Kaiser, Harold ^a,b   Parasuraman, Bhash ^c   Boggs, Robert ^c,e   Miller, Christopher J ^c   Leidy, Nancy Kline ^d   O'Dowd, Liza ^c  

^a Allergy and Asthma Specialists   (United States)

^b Clinical Research Institute   (United States)

^c ASTRAZENECA   (United Kingdom)

^d UNITED BIOSOURCE CORPORATION   (United States)

^e Wyeth Pharmaceuticals

Author keywords

[No Author keywords available]

Indexed keywords

BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; CORTICOSTEROID; FORMOTEROL; PLACEBO; SALBUTAMOL;

ADOLESCENT; ADULT; ARTICLE; ASTHMA; BRONCHODILATATION; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; MAJOR CLINICAL STUDY; MALE; METERED DOSE INHALER; PATIENT SATISFACTION; PRIORITY JOURNAL;

EID: 51649096396     PISSN: 10811206     EISSN: 15344436     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)60495-4     Document Type: Article

References (25)

1. National Asthma Education and Prevention Program. Expert Panel Report: guidelines for the diagnosis and management of asthma - update on selected topics 2002. J Allergy Clin Immunol. 2002;110(suppl):S141-S219.
2. Bender B, Milgrom H, Rand C. Nonadherence in asthmatic patients: is there a solution to the problem? Ann Allergy Asthma Immunol. 1997;79:177-186.
3. Lai CKW, de Guia TS, Kim YY, et al; Asthma Insights and Reality in Asia-Pacific Steering Committee. Asthma control in the Asia-Pacific region: the Asthma Insights and Reality in Asia-Pacific Study. J Allergy Clin Immunol. 2003;111:263-268.
4. Palmqvist M, Arvidsson P, Beckman O, Peterson S, Lötvall J. Onset of bronchodilation of budesonide/formoterol vs. salmeterol/fluticasone in single inhalers. Pulm Pharmacol Ther. 2001;14:29-34.
5. van der Woude HJ, Boorsma M, Bergqvist PBF, Winter TH, Aalbers R. Budesonide/formoterol in a single inhaler rapidly relieves methacholine-induced moderate-to-severe bronchoconstriction. Pulm Pharmacol Ther. 2004;17:89-95.
6. Balanag VM, Yunus F, Yang P-C, Jorup C. Efficacy and safety of budesonide/formoterol compared with salbutamol in the treatment of acute asthma. Pulm Pharmacol Ther. 2006;19:139-147.
7. Jonkers RE, Bantje TA, Aalbers R. Onset of relief of dyspnoea with budesonide/formoterol or salbutamol following methacholine-induced severe bronchoconstriction in adults with asthma: a double-blind, placebo-controlled study. Respir Res. 2006;7:141.
8. Corren J, Korenblat PE, Miller CJ, O'Brien CD, Mezzanotte WS. Twelve-week, randomized, placebo-controlled, multicenter study of the efficacy and tolerability of budesonide and formoterol in one metered-dose inhaler compared with budesonide alone and formoterol alone in adolescents and adults with asthma. Clin Ther. 2007;29:823-843.
9. Noonan M, Rosenwasser LJ, Martin P, O'Brien CD, O'Dowd L. Efficacy and safety of budesonide and formoterol in one pressurised metered-dose inhaler in adults and adolescents with moderate to severe asthma: a randomised clinical trial. Drugs. 2006;66:2235-2254.
10. Ankerst J, Lötvall J, Cassidy S, Byrne N. Comparison of the bronchodilating effects of formoterol and albuterol delivered by hydrofluoroalkane pressurized metered-dose inhaler. Treat Respir Med. 2005;4:123-127.
11. Rodrigo GJ. Rapid effects of inhaled corticosteroids in acute asthma: an evidence-based evaluation. Chest. 2006;130:1301-1311.
12. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis. 1987;136:225-244.
13. American Thoracic Society. Lung function testing: selection of reference values and interpretative strategies. Am Rev Respir Dis. 1991;144:1202-1218.
14. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention: WHO/NHLBI Workshop Report. Bethesda, MD: National Heart, Lung, and Blood Institute, National Institutes of Health; updated 2003. NIH publication 02-3659.
15. National Asthma Education and Prevention Program. Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma. Bethesda, MD: National Heart, Lung, and Blood Institute, National Institutes of Health; 1997. NIH publication 97-4051.
16. Leidy N, Patrick D, Parasuraman B, Petrillo J, Mathias S. Can patients with asthma feel their maintenance inhaler working right away? reproducibility and validity of a method for assessing perception and satisfaction. Poster presented at: 12th Annual Meeting of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR); May 19-23, 2007; Arlington, VA.
17. Mathias S, Parasuraman B, Petrillo J, Leidy N. Understanding patient perception of therapy: development of a weekly diary to determine whether patients with asthma can feel their maintenance inhaler working right away. Poster presented at: 12th Annual Meeting of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR); May 19-23, 2007; Arlington, VA.
18. Palmqvist M, Persson G, Lazer L, Rosenborg J, Larsson P, Lötvall J. Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency. Eur Respir J. 1997;10:2484-2489.
19. Enright PL, Lebowitz MD, Cockcroft DW. Physiologic measures: pulmonary function tests: asthma outcome. Am J Respir Crit Care Med. 1994;149:S9-S18.
20. Bellia V, Cibella F, Cuttitta G, et al. Effect of age upon airway obstruction and reversibility in adult patients with asthma. Chest. 1998;114:1336-1342.
21. Borg BM, Reid DW, Walters EH, Johns DP. Bronchodilator reversibility testing: laboratory practices in Australia and New Zealand. Med J Aust. 2004;180:610-613.
22. Haney S, Hancox RJ. Tolerance to bronchodilation during treatment with long-acting β-agonists, a randomised controlled trial. Respir Res. 2005;6:107.
23. Ekström T, Ringdal N, Tukiainen P, Runnerström E, Soliman S. A 3-month comparison of formoterol with terbutaline via turbuhaler: a placebo-controlled study. Respir Med. 1998;81:225-230.
24. Ekström T, Ringdal N, Sobradillo V, Runnerström E, Soliman S. Low-dose formoterol Turbuhaler (Oxis) b.i.d., a 3-month placebo-controlled comparison with terbutaline (q.i.d.). Ann Allergy Asthma Immunol. 1998;92:1040-1045.
25. Bender BG, Long A, Parasuraman B, Tran ZV. Factors influencing patient decisions about the use of asthma controller medication. Ann Allergy Asthma Immunol. 2007;98:322-328.